Today's Date: December 3, 2022
MSCI Uplifted GTJAl's ESG Rating, Stating That Its Corporate Governance Leads Global Peers   •   OPENDOOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Op   •   GENERAC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Generac Holdings, In   •   Canada Revenue Agency's Disability Advisory Committee submits 10 recommendations in its third annual report   •   Dennis Amos, Vice President of Planning & Analysis for The Twenty-Nine Palms Band of Mission Indians, "QCI's Dynamic Reinves   •   Leading National Prostate Cancer Nonprofit Spearheads Influential HHS Moonshot Meeting   •   Reducing licensed child care fees for British Columbia families by 50%   •   The Law Offices of Frank R. Cruz Announces Investigation of Generac Holdings Inc. (GNRC) on Behalf of Investors   •   PROVIDENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Provident Bancorp, Inc. on Behalf of Provident Stockholders an   •   INVESTOR DEADLINE: Olaplex Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit &ndash   •   Ismael Cala invites you to plan and manifest 2023 as the best year of our lives   •   Bark Technologies Announces a Strategic MVNO Agreement with T-Mobile Enabling Mobile Service for its Bark Phone Featuring Childr   •   EHEALTH INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Of   •   Louisiana local Ronnie Schwartz clinches St. Jude Hero Among Us Award   •   'Tis the Season for Giving Back at Jim Ellis Automotive   •   The Canadian Association of Journalists is now accepting nominations for its 2022 Awards program   •   GENERAC HOLDINGS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losse   •   Savory & Partners: Birthright citizenship and the exciting world of birth tourism   •   PAYPAL HOLDINGS, INC. DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Fil   •   Jack Nathan Health Provides Corporate Update
Bookmark and Share

Evofem Biosciences Announces Approval of Phexxi in Nigeria

Evofem Biosciences Announces Approval of Phexxi in Nigeria

PR Newswire

-- First Regulatory Approval Outside the U.S. --

SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). 

This marks the Company's first approval outside the United States. Regulatory dossiers have also been submitted in Ghana, Ethiopia and Mexico. The product will be potentially marketed under the brand name Femidence™.   

Nigeria is the most populous country in Africa and the seventh largest country in the world, with 45 million women of reproductive age. With nearly half of the population under the age of 18 years, a record number of young people will enter reproductive age in the next decade.

In October 2020, Adjuvant Capital made a $25 million strategic investment to expand global market access for Phexxi® (lactic acid, citric acid, potassium bitartrate) vaginal contraceptive gel and to support EVOGUARD, Evofem's registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women. Evofem is on track to report top-line data from this landmark trial in mid-October 2022. Positive study outcomes would enable regulatory submissions and potential U.S. approval for prevention of these sexually transmitted infections in 2023. 

"We expect Nigeria will be one of many commercial markets around the world in which Evofem can generate shareholder returns while favorably impacting the lives of women," said Jenny Yip, Managing Partner at Adjuvant Capital and a Director of Evofem Biosciences. "Women everywhere are demanding more contraceptive choices to suit their needs, and they specifically want non-hormonal options, like Phexxi, that are free from common side effects like depression, mood swings and irritability." 

Evofem is grateful to DKT Nigeria, its distribution partner in Nigeria, for their support of this registration.

About Evofem Biosciences

Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data in mid-October 2022 from its registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark and Femidence™ is a trademark of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including our ability to successfully commercialize Phexxi outside of the U.S. and general market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022,  and subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contacts

Investors:

Amy Raskopf

SVP, Investor Relations

Evofem Biosciences, Inc.

araskopf@evofem.com

(917) 673-5775

Media:

media@evofem.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-approval-of-phexxi-in-nigeria-301642132.html

SOURCE Evofem Biosciences, Inc.



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News